-

BW Fusion, Biodyne, and Agronomy 365 Join to Revolutionize Agriculture Industry, Supported by Bain Capital Double Impact

Union of three companies creates market-leading platform for crop nutrition and grower support to empower U.S. farming communities

FORT WAYNE, Ind. & FONDA, Iowa--(BUSINESS WIRE)--BW Fusion, an innovator in agricultural crop and soil nutrition; Biodyne, an environmental microbiology company; and Agronomy 365, a tech-enabled crop analytics and management program; today announced their merging to create an integrated platform under BW Fusion. The combined company will offer growers more effective and sustainable biologicals at every stage of the crop nutrition cycle. The transaction formalized a previous strategic alliance between the three companies and will accelerate product innovations and enhance grower support. Financial support for the transaction was provided by Bain Capital Double Impact, the impact investing arm of Bain Capital.

In 1989, Dr. Fred Farley, an esteemed microbiologist and plant physiologist founded Biodyne and began developing beneficial microbes for environmental stewardship and bioremediation. His research was applied to hundreds of plant and vegetation species, proving efficacy to reduce soil contamination and improve overall plant health. In 2012, seeing the promise of Dr. Farley’s work, Gil Farley and Tim Weir formed a new venture to commercialize Biodyne’s products. These efforts later led to a partnership with third-generation grower Grant Wells and the founding of BW Fusion in 2019 with a focus on row crops such as corn, soy and wheat. As BW Fusion expanded, a partnership with Jason Schley and Agronomy 365 was formed.

Going forward, BW Fusion will marry Biodyne’s 30+ years of biologicals research, Agronomy 365’s cutting-edge data and software tools, and BW Fusion’s product development, manufacturing and commercial expertise to support farming communities across the U.S. BW Fusion is poised to benefit from long-term secular tailwinds in agriculture and increasing demand for environmentally sustainable biological crop nutrition solutions.

“Our mission has always been to help growers improve crop productivity and long-term soil health. As farmers ourselves, we understand the importance of providing growers with the right data to make informed decisions. Through our partnership to date, it’s evident that leveraging our combined strengths supports growers with the resources they need at scale to improve farming methods and increase long term profits,” said Jason Schley, BW Fusion’s Chief Agronomist and Product Officer. “BW Fusion’s products are now used on over 1 million acres across the U.S., and we are excited to partner with Bain Capital Double Impact to continue supporting farming communities while simultaneously helping the environment win,” said Grant Wells, a Partner at BW Fusion.

We are excited to collaborate with the founders to create a complete solution that fuses leading agronomy, environmental microbiology, and grower-support to accelerate BW Fusion’s impact” said Jacob Donnelly, a Partner at Bain Capital Double Impact. “Our investment in the BW Fusion platform reflects our strategy of partnering with mission-driven companies to help them scale and achieve greater climate and sustainability results.”

Financial terms of the private transaction were not disclosed.

About BW Fusion

BW Fusion, an innovator in agricultural crop and soil nutrition; Biodyne, an environmental microbiology company; and Agronomy 365, a tech-enabled crop analytics and management program; merged to create an integrated platform under BW Fusion. The combined company offers growers more effective and sustainable biologicals at every stage of the crop nutrition cycle. For more information on BW Fusion, visit the website at www.bw-fusion.com.

About Bain Capital Double Impact

Bain Capital Double Impact is the impact investing strategy of Bain Capital, a leading global private investment firm. Bain Capital Double Impact leverages deep industry experience and an active, value-added approach to build great companies that deliver both competitive financial returns and meaningful, measurable social and environmental good. Bain Capital Double Impact partners with companies across three themes – health & wellness, education & workforce development, and sustainability to create long-term value and meaningful social impact at scale. For more information, visit www.baincapitaldoubleimpact.com

Contacts

Media
Charlyn Lusk
Stanton
(646) 502-3549
clusk@stantonprm.com

Bain Capital LogoBain Capital Logo

Bain Capital


Release Versions

Contacts

Media
Charlyn Lusk
Stanton
(646) 502-3549
clusk@stantonprm.com

More News From Bain Capital

Bain Capital Specialty Finance, Inc. Announces December 31, 2024 Financial Results and Declares First Quarter 2025 Dividend of $0.42 per Share and Additional Dividends Totaling $0.12 per Share for 2025

BOSTON--(BUSINESS WIRE)--Bain Capital Specialty Finance, Inc. (NYSE: BCSF, the “Company”, “our” or “we”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2024, and that its Board of Directors (the “Board”) has declared a dividend of $0.42 per share for the first quarter of 2025 and has also declared additional dividends totaling $0.12 per share for 2025. “BCSF delivered strong quarterly and full year 2024 results as we continued to benefit from high ne...

Bain Capital Credit Announces $6 Billion of Financing Investments for 2024

BOSTON--(BUSINESS WIRE)--Bain Capital Credit, LP, a leading global credit specialist, today announced that the firm’s Private Credit Group invested $6 billion to support the growth of middle market and private equity-backed companies in 2024. Bain Capital Credit’s Private Credit Group made 97 investments in 2024, supporting the refinancing, leveraged buyout, and add-on acquisition activity of both new and existing portfolio companies. With over 25 years of middle market private debt experience,...

Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (“Tanabe Pharma”, “MTPC” or “the Company”) in a carve-out transaction from Mitsubishi Chemical Group Corporation. The investment is being led by Bain Capital’s Private Equity teams in Asia and North America together with the firm’s Life Sciences team and values the business at approximately 510 billion JPY (...
Back to Newsroom